Caladrius Biosciences And Cend Therapeutics Highlights Publication Of Pancreatic Cancer Trial Data In The Lancet Gastroenterology And Hepatology
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, and Cend